Literature DB >> 21207061

Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.

Bai Zhao1, Tiemin Sun, Fanjuan Meng, Aibing Qu, Chunling Li, Hui Shen, Yu Jin, Wenxin Li.   

Abstract

PURPOSE: Lung cancer is one of the most malignant tumors and poses a significant threat to human health. Osteopontin (OPN) is a variably expressed, secreted glycophosphoprotein that mediates the growth and metastases of several carcinoma types. In this study, we aimed to understand the role of OPN in lung cancer cell proliferation and invasiveness.
METHODS: Expression of OPN was examined using an immunohistochemical method in paraffin-embedded sections collected from 49 patients with lung cancer. We silenced OPN expression by lentivirus-mediated OPN-specific small interfering RNA (siRNA) and examined the proliferation and invasiveness of OPN-silenced lung cancer cell (A549) through MTT, BrdU, flow cytometry, and Matrigel assay. In addition, we tested the role of individual OPN splice variants in A549 cell growth and invasion by constructing OPN overexpression lentiviruses. RESULT: Downregulation of OPN inhibited A549 cell proliferation and in vivo tumor growth, abrogated augmentation of invasion, induced G1-phase cell cycle arrest, and induced cell late apoptosis and necrosis. Moreover, the proliferation and invasiveness was linked to different OPN splice variants, of which OPN-b affected the cell proliferation and OPN-c showed significant correlation with invasion behavior.
CONCLUSIONS: Our data suggested that OPN served as a potential biomarker for invasive lung cancer and provided new molecular-targeted therapy for lung cancer based on lentivirus-mediated RNA interference.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207061     DOI: 10.1007/s00432-010-0968-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  Co-expression of osteopontin and CD44v9 in gastric cancer.

Authors:  T Ue; H Yokozaki; Y Kitadai; S Yamamoto; W Yasui; T Ishikawa; E Tahara
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

2.  Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.

Authors:  Chandra M V Goparaju; Harvey I Pass; Justin D Blasberg; Nathalie Hirsch; Jessica S Donington
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

3.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

Review 4.  The role of osteopontin in breast cancer: clinical and experimental studies.

Authors:  A B Tuck; A F Chambers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

6.  Osteopontin as a potential diagnostic biomarker for ovarian cancer.

Authors:  Jae-Hoon Kim; Steven J Skates; Toshimitsu Uede; Kwong-kwok Wong; John O Schorge; Colleen M Feltmate; Ross S Berkowitz; Daniel W Cramer; Samuel C Mok
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

7.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

8.  Serial plasma osteopontin levels have prognostic value in metastatic breast cancer.

Authors:  Vivien H C Bramwell; Gordon S Doig; Alan B Tuck; Sylvia M Wilson; Katia S Tonkin; Anna Tomiak; Francisco Perera; Theodore A Vandenberg; Ann F Chambers
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

9.  An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.

Authors:  V Takafuji; M Forgues; E Unsworth; P Goldsmith; X W Wang
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

Review 10.  RNA interference: past, present and future.

Authors:  Tessa N Campbell; Francis Y M Choy
Journal:  Curr Issues Mol Biol       Date:  2005-01       Impact factor: 2.081

View more
  16 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Influence of osteopontin silencing on survival and migration of lung cancer cells.

Authors:  B Polat; G Wohlleben; A Katzer; C S Djuzenova; A Technau; M Flentje
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

Review 3.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

4.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.

Authors:  C Ostheimer; C Evers; M Bache; T Reese; D Vordermark
Journal:  Strahlenther Onkol       Date:  2018-01-16       Impact factor: 3.621

5.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

6.  Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Authors:  Farbod Shojaei; Nathan Scott; Xiaolin Kang; Patrick B Lappin; Amanda A Fitzgerald; Shannon Karlicek; Brett H Simmons; Aidong Wu; Joseph H Lee; Simon Bergqvist; Eugenia Kraynov
Journal:  J Exp Clin Cancer Res       Date:  2012-03-23

7.  Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.

Authors:  Tímea Kiss; Krisztina Jámbor; Viktória Koroknai; István Szász; Helga Bárdos; Attila Mokánszki; Róza Ádány; Margit Balázs
Journal:  Pathol Oncol Res       Date:  2021-03-05       Impact factor: 3.201

8.  Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer.

Authors:  Seon-Sook Han; Seung-Joon Lee; Woo Jin Kim; Dong Ryeol Ryu; Jun Yeon Won; Shinyoung Park; Myeong Ju Cheon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-09-30

9.  Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Kjetil Boye; Miriam Oijordsbakken; Marius Lund-Iversen; Ann Rita Halvorsen; Steinar K Solberg; Gisle Berge; Aslaug Helland; Odd Terje Brustugun; Gunhild M Mælandsmo
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

10.  OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC.

Authors:  Yanzhang Hao; Jianwei Liu; Ping Wang; Feng Wang; Zeshun Yu; Mianli Li; Shaoshui Chen; Fangling Ning
Journal:  Int J Genomics       Date:  2014-08-05       Impact factor: 2.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.